SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (491)1/1/1998 2:52:00 PM
From: Dauntless   of 834
 
FDA info #1

For those of you who are maybe not in the business & wonder about some of the recent claims on this site, I thought this info might be enlightening.

The following is a brief description of the clinical trials process & the "survival rates" for drugs at each phase. This info can be found at:

fda.gov

====================================================================
Testing in Humans

Phase 1
Number of Patients: 20-100
Length: Several months
Purpose: Mainly safety
Percent of Drugs Successfully Tested*: 70 percent

Phase 2
Number of Patients: Up to several hundred
Length: Several months to 2 years
Purpose: Some short-term safety but mainly effectiveness
Percent of Drugs Successfully Tested*: 33 percent

Phase 3
Number of Patients: Several hundred to several thousand
Length: 1-4 years
Purpose: Safety, dosage, effectiveness
Percent of Drugs Successfully Tested*: 25-30 percent

* For example, of 100 drugs for which investigational new drug applications are submitted to FDA, about 70 will successfully complete phase 1 trials and go on to phase 2; about 33 of the original 100 will complete phase 2 and go to phase 3; and 25 to 30 of the original 100 will clear phase 3 (and, on average, about 20 of the original 100 will ultimately be approved for marketing).

====================================================================

NOTICE - Out of 100 drugs that start the clinical trial process, approximately 25 - 30 will clear Phase III testing and "about 20 will ultimately be approved for marketing" - that's 66.7 - 80% of those finishing Phase III. Some time ago I estimated a slightly higher percentage than that (I think I said 85-90%) & I still think that's correct for certain circumstances - low side effects, no alternative therapies, entity submitting the NDA (large pharma does better than little guys),etc. In any event, based on FDA supplied statistics, Vasomax appears to have a pretty good chance of receiving FDA marketing approval - especially with a big pharma partner handling the NDA - they don't just provide $ & distribution.

For what it's worth - an opinion, but backed up with FDA published data (read: real proof) - for a change.

I urge anyone that's interested to look around the FDA link I provided - lots of "stuff" to help you evaluate the information provided, by some, on this site.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext